title: Photodynamic Therapy for Choroidal Metastasis.
abstract: OBJECTIVE
  To evaluate the effectiveness of photodynamic therapy (PDT) in the management of choroidal metastasis.
  
  
  METHODS
  Retrospective, interventional case series.
  
  
  METHODS
  Patients with choroidal metastasis treated with PDT at a single institution were reviewed. PDT was applied with verteporfin at a dose of 6 mg/m(2) body surface area and a 689 nm diode laser for 83 seconds. Visual acuity, tumor basal diameter, tumor thickness by ultrasonography, and enhanced depth imaging optical coherence tomography (EDI-OCT), as well as associated features including subretinal fluid, were recorded before PDT and during follow-up examinations.
  
  
  RESULTS
  Twenty-one tumors in 13 eyes of 10 patients were included. Eight tumors were treated with a single session of PDT, 11 tumors received 2 sessions, 1 tumor received 3 sessions, and 1 tumor received 5 sessions. At the end of a mean follow-up of 12 months (range, 3-42 months), 9 eyes (69%) had stable or improved visual acuity, while 4 eyes (31%) had decreased visual acuity. Mean logMAR change in visual acuity was -0.09 (range, -1.3 to 0.8). Seventeen of 21 tumors (81%) were flat at last follow-up. The mean decrease in ultrasound-measured thickness was 0.83 mm (range, 2.6 mm decrease to 1.4 mm increase), while the decrease in EDI-OCT-measured thickness was 400 μm (range, 1280 μm decrease to 280 μm increase). Eighteen tumors (86%) had complete resolution of subretinal fluid. There were no PDT-related complications.
  
  
  CONCLUSIONS
  Photodynamic therapy may be an effective therapeutic option for the management of choroidal metastasis in selected cases.
authors.affiliation: Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan.
authors.forename: Devon H
authors.initials: DH
authors.lastname: Ghodasra
authors.affiliation: Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan. Electronic address: hdemirci@med.umich.edu.
authors.forename: Hakan
authors.initials: H
authors.lastname: Demirci
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000473:pathology; D002277:Carcinoma / Q000188:drug therapy / Q000556:secondary; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000556:secondary; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000556:secondary; D002291:Carcinoma, Papillary; D002830:Choroid Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007834:Lasers; D008175:Lung Neoplasms / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D012189:Retrospective Studies; D058471:Subretinal Fluid; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000556:secondary; D041623:Tomography, Optical Coherence; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin